Inflammation

  • Is an agent used to treat psoriasis aimed at the wrong target?

    Common psoriasis, also called psoriasis vulgaris, is an inflammatory skin disease. Source Helmholtz Zentrum München

    The antibody ustekinumab is in use for treatment of psoriasis since 2009. It inhibits the underlying inflammation by neutralizing certain messengers of the immune system. Researchers at the Helmholtz Zentrum München, the Technical University of Munich and the University of Zurich have now shown in ‘Nature Communications’ that one of these messengers could actually be helpful in battling the illness. Common psoriasis, also called psoriasis vulgaris, is an inflammatory skin disease that is characterized by severely scaling skin in areas ranging from small to palm-sized. The disease is estimated to affect between two and three percent of all Europeans.

  • Münster researchers make ongoing inflammation in the human brain visible

    Researchers at the Cells-in-Motion Cluster of Excellence have visualized inflammation in the brain of mice (l.) and of MS patients (r.). To do so, they labelled specific enzymes (MMPs). Reprinted with permission from Gerwien and Hermann et al., Sci. Transl. Med. 8, 364ra152 (2016) 9 November 2016

    For the first time, Researchers at the Cells-in-Motion Cluster of Excellence (CiM) at Münster University have been able to image ongoing inflammation in the brain of patients suffering from multiple sclerosis. The ultimate aim in biomedical research is the transfer of results from experiments carried out in animals to patients. Researchers at the Cells-in-Motion Cluster of Excellence (CiM) at the University of Münster have succeeded in doing so. For the first time, they have been able to image ongoing inflammation in the brain of patients suffering from multiple sclerosis (MS). This involved specialists from different disciplines working together in a unique way over several years, combining immunology, neurology and imaging technologies ranging from microscopy to whole-body imaging.

  • Newly discovered bacteria-binding protein in the intestine

    Joakim Bergström Photo: Cecilia Hedström

    Deficiency in a certain protein in the gastrointestinal tract has been shown to lead to both inflammation and abdominal fat accumulation in mice. The discovery provides yet another piece of the puzzle of how humans are affected — or not — by the large quantities of intestinal bacteria we carry with us. In the study from Sahlgrenska Academy, researchers have addressed the key role of the bacteria-binding protein ZG16 in protecting the body from intestinal bacteria. “The hope is that eventually, we’ll be able to administer this protein to improve protection against bacteria in patients with a defective barrier,” says Joakim Bergström, postdoctoral researcher at Sahlgrenska Academy. Joakim Bergström is in Professor Gunnar C. Hansson’s research group, which, eight years ago, was first to discover that there is a protective mucus layer in the intestine that separates intestinal bacteria from the intestinal surface.